share_log

HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Raises Price Target to $7.5

Benzinga ·  Mar 26 18:24

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $6 to $7.5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment